Medicines impact the lives of millions of people and strengthen their well-being, but there are risks involved in their use. Scientists agree that risk assessment during drug development should be carried out rigorously, but identifying safety concerns during clinical trials is complex. Pharmacovigilance is a field of science dedicated to the understanding and prevention of the adverse effects of medicines. The Med-ePHV (Learning and practicing pharmacovigilance in the Mediterranean countries) project, funded under the EU's Sixth Framework Programme (FP6) with EUR 804,420, has proposed an innovative approach to EU pharmacovigilance practice.
Health practitioners and patients are the first to recognise Adverse Drug Reactions (ADR) and to notify the appropriate authorities. But the process is complicated by inefficient delivery of notifications to both national and European agencies.
EU pharmaceutical regulators stress the importance of pharmacovigilance to the well-being of European citizens. Med-ePHV sought to design and implement a cooperative e-learning system that addresses the needs and profiles of Mediterranean-based health practitioners and patients, in particular those from Spain, France and Italy.
The project partners believed their innovative system 'would allow the parties involved to learn and practise ADRs notification at the peripheral edge of the pharmacovigilance systems'.
The team also aimed to develop pharmacovigilance e-learning courses and tutoring strategies that comply with EU legislation and can be adapted to the needs of national implementation schemes. They targeted the testing and validation of the e-learning modules in a representative sample of health practitioners and selected pharmaceutical industry representatives.
Finally, the researchers sought to design a cooperative environment as the central component of an 'application grid' that would be accessible to local health authorities and health practitioners. Partnership agreements would then be forged so that the e-learning modules could be commercially exploited.
Launched in September 2006, the grid-based computing platform included an online pilot for training on ADRs notification and reporting that complied with established international standards, and 'pharmacovigilance e-learning courses and tutoring schemes' that both supported knowledge-based ADRs specification and addressed correlation and standardisation issues.
Participating in the project were the small- and medium-sized enterprises (SMEs) Arisoft Editorial (Spain), PasteurMediavita (France) and Gruppo S LAB (Italy). The Spanish group specialises in internet portals targeting the promotion of specialised training programmes in various sectors such as health. PasteurMediavita offers specialised, health-related conventional and internet support training, and Gruppo supplies medical information products.
The SMEs worked together with research and technology development groups, including France's National Institute of Health and Medical Research and the University of Pavia in Italy, to make the project a success. The European Forum of Clinical Good Practice also took part by raising awareness of the project's results at the EU level.
For futher information, please visit:
http://www.medephv.net
Copyright ©European Communities, 2009
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.
Business & Industry
- Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
- Darolutamide meets primary endpoint in Phase III ARANOTE trial
- Pfizer advances development of once-daily formulation of oral GLP-1 receptor agonist danuglipron
- AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease
- GSK and CureVac to restructure collaboration into new licensing agreement
Research & Development
- Data from largest clinical trial of pre-symptomatic Alzheimer's disease now widely available
- Fighting antibiotic resistance with peptide cocktails
- Novel drug application shows improved survival for patients with relapsed and refractory acute myeloid leukemia
- Study shows ancient viruses fuel modern-day cancers
- New AI approach optimizes antibody drugs
- A comprehensive derivative synthesis method for development of new antimicrobial drugs
- Delaying diabetes with diet and exercise for 4 years results in better long-term health
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy
- FDA approves first gene therapies to treat patients with sickle cell disease
- FDA approves first therapy for rare type of non-cancerous tumors
- First electronic product information (ePI) published for selected human medicines
- FDA approves first treatment for patients with rare inherited blood clotting disorder